Pioneering Changes in Psychiatry: Biomarkers, Psychedelics, and AI.
ACS Med Chem Lett August 18, 2023 DOI: 10.1021/acsmedchemlett.3c00333 via PubMed Central
Summary
AI-generated from the abstractThis viewpoint argues that combining biomarkers, psychedelics, and artificial intelligence could improve psychiatric diagnostics, prognosis, and treatment. Psychedelics show promise in therapy, and AI may help predict how individuals will respond to treatments. However, significant challenges remain, including ethical and practical hurdles. The authors call for further research to develop more precise, personalized psychiatric care.
Study at a glance
| Characteristics | Viewpoint Peer reviewed |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Keywords | Mental health Personalized medicine Medical innovation Ai in healthcare |
| Citations | 3 |
| Key finding | Integrating biomarkers, psychedelics, and AI could enhance personalized psychiatric care, but challenges must be addressed. |
Abstract
This viewpoint discusses integrating biomarkers, psychedelics, and AI into psychiatry for enhanced diagnostics, prognosis, and treatment. It highlights the potential of psychedelics in therapy, AI's role in predicting treatment response, and the challenges that must be addressed. The aim is to encourage research for more precise, personalized psychiatric care.